Obsidian Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Obsidian Therapeutics, Inc. Common Stock (OBX) has an Asset Resilience Ratio of 46.08% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See OBX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Obsidian Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see OBX total assets.
Liquid Assets Composition Over Time
This chart breaks down Obsidian Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Obsidian Therapeutics, Inc. Common Stock debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $32.32 Million | 46.08% |
| Total Liquid Assets | $32.32 Million | 46.08% |
Asset Resilience Insights
- Very High Liquidity: Obsidian Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 46.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Obsidian Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Obsidian Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Obsidian Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Obsidian Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 45.25% | $40.08 Million | $88.58 Million | -19.26pp |
| 2024-12-31 | 64.51% | $118.51 Million | $183.71 Million | -- |
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform de… Read more